Relationship between bone resorption, oxidative stress and inflammation in severe COPD exacerbation

Clinical Biochemistry

Volumn 46, Issue 16-17, 2013, Pages 1678-1682

  Stanojkovic, Ivana ^a   Kotur Stevuljevic, Jelena ^a   Spasic, Slavica ^a   Milenkovic, Branislava ^a,b   Vujic, Tatjana ^a,b   Stefanovic, Aleksandra ^a   Ivanisevic, Jasmina ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Bone resorption; COPD exacerbation; Inflammation; Oxidative stress

Indexed keywords

BETA ISOMERIZED C TERMINAL TELOPEPTIDE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; FEMALE; GEOMETRY; HEALTH CENTER; HUMAN; HYPOXIA; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; NEUTROPHIL COUNT; OSTEOLYSIS; OSTEOPOROSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

BONE RESORPTION; COPD EXACERBATION; INFLAMMATION; OXIDATIVE STRESS;

BIOLOGICAL MARKERS; BONE RESORPTION; CASE-CONTROL STUDIES; COLLAGEN TYPE II; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; LINEAR MODELS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84886381846     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.08.003     Document Type: Article

References (42)

1. Agusti A. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007, 4:522-525.
2. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., Busqets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:347-360.
3. Decramer M., Rennard S., Troosters T., et al. COPD as a lung disease with systemic consequences-clinical impact, mechanisms, and potential for early intervention. COPD 2008, 5(4):235-256.
4. Lehouck A., Boonen S., Decramer M. COPD, bone metabolism and osteoporosis. Chest 2011, 139(3):648-657.
5. Bolton C.E., Ionescu A.A., Shiels K.M. Associated loss of fat free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 170(12):1286-1293.
6. MacNee W., Tuder M.R. New paradigms in the pathogenesis of chronic obstructive respiratory disease I. Proc Am Thorac Soc 2009, 6:527-531.
7. Anderson T.L., del Carem Ovejero M., Kirkegaard T., Lenhard T., Foged N.T., Delaissé J.M. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone 2004, 35:1107-1119.
8. Bonde M., Qvist P., Fledelius C., Riis B.J., Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994, 40(11):2022-2025.
9. Donaldson G.C., Seemungal T.A., Bhowmik A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57(10):847-852.
10. Seemungal T.A., Donaldson G.C., Paul E.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1418-1422.
11. Gunen H., Hacievliyagil S.S., Kosar F. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005, 26(2):234-241.
12. Kiyokawa H., Muro S., Oguma T., et al. Impact of COPD exacerbation on osteoporosis assessed by chest CT scan. COPD 2012, 9:235-242.
13. Groenewegen K.H., Dentener M.A., Wouters E.F. Longitudinal follow-up of systemic inflammation after acute exacerbations of COPD. Respir Med 2007, 101(11):2409-2415.
14. Bolton C.E., Stone M.D., Edwards P.H., Duckers J.M., Evans W.D., Shale D.J. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009, 6:81-87.
15. Rabe K.F., Hurd S., Anzueto A., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
16. Rodriguez Roisin R. Toward a consensus definition for COPD exacerbation. Chest 2000, 117(Suppl. 2):398S-401S.
17. Miller M.R., Crapo R., Hankinson J., Brusasco V., et al. Standardisation of spirometry ATS/ERS task force: standardization of lung function testing. Eur Respir J 2005, 26:319-338.
18. Erel O. A new automated method for measuring total oxidant status. Clin Biochem 2005, 38:1103-1111.
19. Kotur-Stevuljevic J., Spasic S., Stefanovic A., Zeljkovic A., et al. Paraoxonase-1 (PON1) activity, but PON1(Q192R) phenotype, is a predictor of coronary artery disease in a middle-aged Serbian population. Clin Chem Lab Med 2006, 44:1206-1213.
20. Burgeson R.E. New collagens, new concepts. Annu Rev Cell Biol 1988, 4:551-577.
21. Fledelius C., Johnesen A., Cloos P., Bonde M., Qvist P. Identification of a β-isomerised aspartyl residue within the c-terminal telopeptide α1 chain of type I collagen. Possible relation to aging of bone. J Bone Miner Res 1996, 11(Suppl.1). (Abstract No. 113).
22. Garnero P., Sornay-Rendu E., Duboeuf F., Delmas P.D. Markers of bone turnover predict postmenopausal forearm bone loss over 4years: the OFELY study. J Bone Miner Res 1999, 14:1614-1621.
23. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., Wouters E.F. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005, 82:53-59.
24. Engelen M.P., Deutz N.E., Wouters E.F., Schols A.M. Enhanced levels of whole-body protein turnover in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162:1488-1492.
25. Ito I., Nagai S., Handa T., Muro S., Hirai T., Tsukino M., et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005, 172:1378-1382.
26. Elkington P.T., Friedland J.S. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006, 61:259-266.
27. Cataldo D., Munaut C., Noel A., et al. Matrix metalloproteinases and TIMP-1 production by peripheral blood granulocytes from COPD patients and asthmatics. Allergy 2001, 56:145-151.
28. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:2645-2653.
29. Pinto-Plata V., Toso J., Lee K., Park D., Bilello J., Mullerova H., et al. Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax 2007, 62:595-601.
30. Aldonyte R., Jansson L., Piitulainen E., Janciauskiene S. Circulating monocytes from healthy individuals and COPD patients. Respir Res 2003, 4:11.
31. Wouters E.F. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002, 57:1067-1070.
32. Gan W.Q., Man S.F., Senthilselvan A., Sin D.D. Association between chronic obstructive respiratory disease and systemic inflammation: a systemic review and meta-analysis. Thorax 2004, 59:574-580.
33. Man S.F., Connett J.E., Anthonisen N.R., Wise R.A., Tashkin D.P., Sin D.D. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006, 61:849-853.
34. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255.
35. Biskobing D.M. COPD and osteoporosis. Chest 2002, 121(2):609-620.
36. Burnet D., Hill S.L., Chamba A., Stockley R.A. Neutrophils from subjects with chronic obstructive disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987, 2:1043-1046.
37. Rahman I., Morrison D., Donaldson K., MacNee W. Systemic oxidative stress in asthma, COPD and smokers. Am J Respir Crit Care Med 1996, 154:1055-1060.
38. MacNee W. Antioxidants. New drugs for asthma, allergy and COPD 2001, 151-155. Karger, Basel, Switzerland. T.T. Hansel, P.J. Barners (Eds.).
39. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:50-60.
40. Işik B., Işik R., Yolaçan H., Işik M. Serum malonyldialdehyde and paraoxonase levels in chronic obstructive pulmonary disease. Turk Respir J 2005, 6(1):19-21.
41. Tolgyesi G., Molnar V., Semsei A.F., Kiszel P., Ungvari I., Pocza P., et al. Gene expression profiling of experimental asthma reveals a possible role of paraoxonase-1 in the disease. Int Immunol 2009, 21:967-975.
42. Takabatake N., Nakamura H., Abe S., et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-α system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1179-1184.